# Adaptimmune

**Canonical:** https://apis.io/providers/adaptimmune/  
**Website:** https://www.adaptimmune.com/  
**APIs profiled:** 0

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The company leverages its proprietary TCR platform to engineer T cells that can recognize and target a broad range of tumor antigens, aiming to provide transformative treatments across multiple cancer indications. Adaptimmune collaborates with academic, biotech, and pharmaceutical partners to advance its pipeline through preclinical and clinical development, emphasizing safety, efficacy, and innovative manufacturing processes.

## Kin Score — 9.0 / 100 (minimal)

Scored 2026-10-31 under rubric 0.25.0.

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 21.1 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 13.7 (matched via fallback).

## Agent readiness — 3.1 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | documented |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **Adaptimmune Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biopharma, Immunotherapy, TCR, Oncology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/adaptimmune/). Scores are computed from the provider's own public artifacts under a published rubric.